Effect of Herbal Medicine on Vaginal Epithelial Cells: A Systematic Review and Meta-analysis

Yousef Rahmani¹, Khadijeh Chaleh Chaleh¹², Afshar Shahmohammadi¹, Shahla Safari¹

¹Clinical Research Development Center, Imam Ali and Taleghani Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran, ²Department of Medical Surgical Nursing, Kermanshah University of Medical Science, Imam Reza Hospital, Kermanshah, Iran

Objectives: The present meta-analysis aimed to assess the effect of the herbal medicine on the vaginal epithelial cells (VECs) among the menopausal subjects.

Methods: The literature related to VECs exposed to various herbal medicines in menopausal women were searched on three databases, MEDLINE (1966-August 2017), Scopus (1990-August 2017) and Cochrane Library (Cochrane Central Register of Controlled Trials; 2014).

Results: Totally, the meta-analysis was conducted on 11 randomised controlled trials. Based on the findings, the standardized mean difference (SMD) of maturation value (MV) was observed to be elevated by 0.48% (95% interval confidence [CI], 0.108–0.871; P = 0.012), as well as the heterogeneity was high (I² = 84%; P < 0.001). The MV revealed a significant increase in soy group (SMD, 0.358; 95% CI, 0.073–0.871; P = 0.014) compared to the control group.

Conclusions: The herbal medicines exhibited a statistically significant effect on the VECs. A significant effect on the VECs was also found in the subgroup analysis of the patients, who received soy. However, further and extensive studies are required to achieve reliable outcomes. (J Menopausal Med 2018;24:11-16)

Key Words: Atrophic vaginitis - Menopause - Phytoestrogens
Materials and Methods

1. Study design

The literature concerning the vaginal epithelial cells (VECs) exposed to various herbal medicines in menopausal women was searched on three databases of MEDLINE (1966–August 2017), Scopus (1990–August 2017) and Cochrane Library (Cochrane Central Register of Controlled Trials: 2014).

The keywords for searching were the relationship between menopause and primrose oil, St. John’s wort, Hypericum-perforatum, Black cohosh, Red clover, Piascledine, Avocado plus, Soy, kava, Cimicifuga racemosa rhizome, Licorice red, Trigonella foenum-graecum, Ginseng, fenugreek, Flaxseed, Dong quai, Vitex Agnus-Castus, Evening primrose oil, Yam, Salvia officinalis, alternative treatments, complementary treatments, Phytomedicine, herbal treatments or herbs.

The study inclusion criteria were the randomised controlled trials assessing oral herbal medicine effects on the maturation

Table 1. Characteristics of 11 randomized trials included in meta-analysis

| References       | Duration (months) | Age (years) | Drop out (%) | Type of treatment (No. of participants)                                      | Quality of studies |
|------------------|-------------------|-------------|--------------|------------------------------------------------------------------------------|--------------------|
| Baird et al.     | 1                 | -           | 6            | Soy foods (n = 63) Regular regimen (n = 24)                                    | 8                  |
| Murkies et al.   | 3                 | 54          | 18           | Soy flour supplement (n = 23) Wheat flour (n = 24)                             | 9                  |
| Carmignani et al.| 4                 | 51          | 0            | Soy supplementation (n = 20) Placebo (n = 20)                                 | 11                 |
| Chiechi et al.   | 6                 | 52          | 43           | Soy-rich diet (n = 22) Regular regimen (n = 41)                               | 8                  |
| Radhakrishnan et al. | 6           | 53          | 15           | Isoflavone powder (n = 44) Casein protein (n = 41)                            | 10                 |
| Knight et al.    | 3                 | 53          | 16           | An isoflavone supplementation in the form of a powdered drink (n = 9) Isocaloric casein-based beverage (n = 11) | 11                 |
| Levis et al.     | 104               | 52          | 43           | Soy for 1 year (n = 71/81) Soy for 2 years (n = 66/76)                        | 11                 |
| Colli et al.     | 24                | 53          | 15           | Flaxseed extract (n = 28) Placebo (n = 25)                                   | 10                 |
| Knight et al.    | 3                 | 54          | 4            | High dose of Red clover (160 mg) (n = 12) High dose of Red clover (40 mg) (n = 13) Controls (n = 12) | 10                 |
| Manonai et al.   | 24                | 48          | 17           | 20, 30, or 50 mg of Pueraria mirifica (n = 52) Placebo (n = 20)               | 10                 |
| D’Anna et al.    | 7                 | 50-70       | 0            | Isoflavone supplement (n = 198) Regular regimen (n = 193)                    | 12                 |

Fig. 1. The process of selection of randomized controlled trials to include in the meta analysis. MV: maturation value.
value (MV),\textsuperscript{11} which is measured following equation:\textsuperscript{10}

\[ MV = (\% \text{ intermediate cells} \times 0.5) + (\% \text{ superficial cells}) \]

2. Data extraction and quality assessment

Two reviewers independently extracted the required data among trials on the databases and the third reviewer was recruited to address the possible disagreements. The data included year of publication, first author, age of participants, rate of drop out, number of patients in the intervention and control groups. According to Physiotherapy Evidence Database (PEDro) scale, the two reviewers performed independently the quality assessment of the trials.

3. Statistical analysis

Comprehensive meta-analysis software\textsuperscript{12} was used to determine the standardized mean difference (SMD) for each study. The high heterogeneity among trials made us to report the data on the basis of Random Effect Model (DerSimonian and Laird method).

**Results**

The selection process of randomized controlled trials (RCTs) for enrolling in the current meta-analysis is illustrated in Fig. 1, and the specifications of the studies have been summarized in Table 1. Overall, eleven studies\textsuperscript{13-23} met our study inclusion criteria. The SMD of the of MV increased up to 0.48\% (95\% confidence interval [CI], 0.108–0.871; \( P = 0.012 \)). The findings revealed high degree of heterogeneity (\( I^2 = 84\%; P < 0.001 \)) (Fig. 2). Therefore, the sensitivity analysis was carried to explore the causes of heterogeneity in cross-over trials. The individually exclusion of each study had no significant changes at the level of heterogeneity. No asymmetry was seen in the funnel plot of the trials assessing the effectiveness of herbal medicine on the of MV (Fig. 3). The absence of the publication bias was confirmed using the Egger’s regression intercept test (\( P = 0.056 \)) (Fig. 2). We also

\begin{table}
\begin{tabular}{|l|c|c|c|c|c|c|c|}
\hline
\textbf{Study name} & \textbf{Stats for each study} & \textbf{Std diff in means} & \textbf{Standard error} & \textbf{Variance} & \textbf{Lower limit} & \textbf{Upper limit} & \textbf{Z-value} & \textbf{p-value} \\
\hline
Manonai \\ Pueraria mirifica & 1.205 & 0.283 & 0.080 & 0.651 & 1.759 & 4.264 & 0.000 \\
D’Anna \\ phytoesrogen genisten & 1.496 & 0.150 & 0.023 & 1.202 & 1.791 & 9.964 & 0.000 \\
Knight \\ redclover & 0.242 & 0.419 & 0.176 & 0.580 & 1.063 & 0.577 & 0.564 \\
Coli \\ flaxseed & 0.141 & 0.276 & 0.076 & 0.811 & 0.399 & 0.513 & 0.608 \\
Baird \\ soy & 0.221 & 0.240 & 0.058 & 0.250 & 0.693 & 0.920 & 0.357 \\
Murkies \\ soy & 0.951 & 0.308 & 0.095 & 0.347 & 1.554 & 3.088 & 0.002 \\
Carmignani \\ soy & 0.162 & 0.317 & 0.100 & 0.782 & 0.459 & 0.510 & 0.610 \\
Chiechi \\ soy & 0.334 & 0.266 & 0.071 & 0.187 & 0.856 & 1.258 & 0.209 \\
Radhakrishnan \\ soy & 0.117 & 0.217 & 0.047 & 0.308 & 0.543 & 0.540 & 0.589 \\
Knight \\ soy & 0.096 & 0.450 & 0.202 & 0.785 & 0.978 & 0.214 & 0.831 \\
Levis \\ soy & 0.737 & 0.174 & 0.030 & 0.396 & 1.077 & 4.237 & 0.000 \\
& 0.489 & 0.195 & 0.038 & 0.108 & 0.871 & 2.512 & 0.012 \\
\hline
\end{tabular}
\end{table}

**Fig. 2.** Effects of herbal medicine on vaginal epithelial cells (%). Horizontal line: 95\% confidence interval (CI), ■: point estimate, ♦: combined overall effect of treatment.

**Fig. 3.** Funnel plot of publication bias.
performed subgroup analysis for the women receiving soy. The MV showed a significant increase by 0.358% (95% CI, 0.073–0.871; \( P = 0.014; \) \( I^2 = 53\% \); \( P = 0.052 \)) (Fig. 4).

**Discussion**

This is the first meta-analysis to explore the herbal medicine effect on the VECs among menopausal women. According to our findings, the herbal medicine has had statistically significant effect on the vaginal atrophy.

The meta-analysis of several trials demonstrated that the SMD of the MV had significantly borderline increase in the soy group compared to the control group. However, heterogeneity was high. We performed the subgroup analysis in which the meta-analysis was limited to the trials evaluating the effectiveness of the soy on the VECs, which a significant increase was found in the effect size compared to previous meta-analyses. In addition, our meta-analysis had lower \( I^2 = 53\% \) homogeneity compared to the previous investigations \( (I^2 = 81\%) \).

A systematic review assessed four trials on the effectiveness of administration of topical isoflavones on vaginal atrophy. The topical isoflavones had a beneficial effect on the vaginal atrophy, However, the authors concluded that there is a need to larger RCTs to confirm their results.

In contrast to our meta-analysis that revealed a significant increase in the MV, a systematic review and meta-analysis recently performed on the effectiveness of phytoestrogen on the MV among menopausal women showed no significant improvement in phytoestrogen group compared to the control group 0.164% (CI, -0.419 to 0.746).

Several limitations present in this meta-analysis included high heterogeneity, low number of trials, small sample size and methodological flaw, which are better to be addressed in the future studies. The high heterogeneity might be related to the variations and duration of treatment so that some trials did not report pre- and post-treatment means and standard deviations. In addition, no intention-to-treat has been reported in a larger portion of studies contained in the meta-analysis. The quality of trials can be improved due to further trials to follow the CONSORT guidelines.

**Conclusion**

According to the findings obtained from our meta-analysis, the use of herbal medicines in different studies showed statistically significant positive effects on the VECs. The subgroup analysis of the patients receiving soy indicated also significant effects on the VECs. However, high heterogeneity among the trials makes ambiguous the definitive conclusions on the beneficial effects of herbal on the VECs.
Conflict of Interest

No potential conflict of interest relevant to this article was reported.

References

1. Abdi F, Mobedi H, Roozbeh N. Hops for menopausal vasomotor symptoms: Mechanisms of action, J Menopausal Med 2016; 22: 62–4.
2. Ghazanfarpour M, Kaviani M, Abdollahian S, Borakchi H, Najmabadi Khadijeh M, Naghvi M, et al. The relationship between women’s attitude towards menopause and menopausal symptoms among postmenopausal women, Gynecol Endocrinol 2015; 31: 860–5.
3. Golshiri F, Akbari M, Abdollahzadeh MR. Age at natural menopause and related factors in Isfahan, Iran, J Menopausal Med 2016; 22: 87–93.
4. Lee HH, Kim TH, Park J, Lee A, Park Y, Byun DW, et al. Expression of ezrin in vagina cells of postmenopausal rats after dietary administration of omega–3 Fatty Acid formula, J Menopausal Med 2014; 20: 97–103.
5. Direkvand–Moghadam A, Delpisheh A, Montazeri A, Sayehmiri K. Quality of life among Iranian infertile women in postmenopausal period: A cross-sectional study, J Menopausal Med 2016; 22: 108–13.
6. Levis S, Strickman–Stein N, Doerge DR, Krischer J. Design and baseline characteristics of the soy phytoestrogens as replacement estrogen (SPARE) study—a clinical trial of the effects of soy isoflavones in menopausal women, Con-temp Clin Trials 2010; 31: 293–302.
7. Kim HK, Kang SY, Chung YJ, Kim JH, Kim MR. The recent review of the genitourinary syndrome of menopause, J Menopausal Med 2015; 21: 65–71.
8. Kaari C, Haidar MA, Junior JM, Nunes MG, Quadros LG, Kemp C, et al. Randomized clinical trial comparing conjugated equine estrogens and isoflavones in postmenopausal women: a pilot study, Maturitas 2006; 53: 49–58.
9. Scarrabin PY, Oger E, Plu–Bureau G. Differential association of oral and transdermal oestrogen–replacement therapy with venous thromboembolism risk, Lancet 2003; 362: 428–32.
10. Ghazanfarpour M, Sadeghi R, Roudsari RL, The application of soy isoflavones for subjective symptoms and objective signs of vaginal atrophy in menopause: A systematic review of randomised controlled trials, J Obstet Gynaecol 2016; 36: 160–71.
11. Moseley AM, Herbert RD, Sherrington C, Maher CG. Evidence for physiotherapy practice: a survey of the Physiotherapy Evidence Database (PEDro), Aust J Physiother 2002; 48: 43–9.
12. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Comprehensive meta–analysis, Englewood, NJ: Biostat; 2005.
13. Baird DD, Umbach DM, Lansdell L, Hughes CL, Setchell KD, Weinberg CR, et al. Dietary intervention study to assess estrogenicity of dietary soy among postmenopausal women, J Clin Endocrinol Metab 1995; 80: 1685–90.
14. Murkies AL, Lombard C, Strauss BJ, Wilcox G, Burger HG, Morton MS. Dietary flour supplementation decreases postmenopausal hot flushes: effect of soy and wheat, Maturitas 1995; 21: 189–95.
15. Carmignani LO, Pedro AO, Costa–Paiva LH, Pinto–Neto AM, The effect of dietary soy supplementation compared to estrogen and placebo on menopausal symptoms: a randomized controlled trial, Maturitas 2010; 67: 262–9.
16. Chiechi LM, Putignano G, Guerra V, Schiavelli MP, Cisternino AM, Carriero C. The effect of a soy rich diet on the vaginal epithelium in postmenopause: a randomized double blind trial, Maturitas 2003; 45: 241–6.
17. Radhakrishnan G, Rashmi NA, Vaid NB. Evaluation of isoflavone rich soy protein supplementation for postmenopausal therapy, Pak J Nutr 2009; 8: 1009–17.
18. Knight DC, Howes JB, Elen JA, Howes LG. Effects on menopausal symptoms and acceptability of isoflavone–containing soy powder dietary supplementation, Climacteric 2001; 4: 13–8.
19. Levis S, Strickman–Stein N, Ganji–Azar P, Xu P, Doerge DR, Krischer J. Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double–blind trial, Arch Intern Med 2011; 171: 1363–9.
20. Colli MC, Bracht A, Soares AA, de Oliveira AL, Böer CG, de Souza CG, et al. Evaluation of the efficacy of flaxseed meal and flaxseed extract in reducing menopausal symptoms, J Med Food 2012; 15: 840–5.
21. Knight DC, Howes JB, Elen JA. The effect of Premensil, an isoflavone extract, on menopausal symptoms, Climacteric 1999; 2: 79–84.
22. Monouai J, Chittacharoen A, Theppisai U, Theppisai H. Effect of Pueraaria mirifica on vaginal health, Menopause 2007; 14: 919–24.
23. D’Anna R, Cannata ML, Atteritano M, Cancelleri F, Corrado F, Baviera G, et al. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 1–year randomized, double–blind, placebo–controlled study, Menopause 2007;
24. Ghazanfarpour M, Latifnejad Roudsari R, Treglia G, Sadeghi R. Topical administration of isoflavones for treatment of vaginal symptoms in postmenopausal women: A systematic review of randomised controlled trials. J Obstet Gynaecol 2015; 35: 783-7.

25. Saghafi N, Ghazanfarpour M, Sadeghi R, Najarkolaei AH, Omid MG, Azad A, et al. Effects of phytoestrogens in alleviating the menopausal symptoms: A systematic review and meta-analysis. Iran J Pharm Res 2017; 16: 99-111.